作者: RICHARD T. SCHEIFE , WENDY R. CRAMER , EDWARD L. DECKER
DOI: 10.1111/J.1365-4362.1993.TB02810.X
关键词: Phototoxicity 、 Internal medicine 、 Lomefloxacin 、 Enoxacin 、 Fleroxacin 、 Medicine 、 Pefloxacin 、 Surgery 、 Ciprofloxacin 、 Ofloxacin 、 Ambulatory
摘要: Background. The relative phototoxic risk of ofloxacin, one the newer fluoroquinolones, was compared with that an active control known but low risk, naproxen. Methods. A randomized, controlled, open-label trial used a standardized assay completed at baseline, midway through, and termination 12-day trial. held dermatology research laboratory located large tertiary referral teaching hospital. Thirty healthy volunteers who met inclusion criteria none exclusion were enrolled. Twenty-seven patients Three subjects failed to complete trail. One subject developed exaggerated response Initial photoexposure dropped from study. other two return for follow-up visits. Results. Both ofloxacin agent, naproxen, significantly increased subjects’ tested solar ultraviolet irradiation. There was, however, no significant difference between responses observed versus naproxen any time. Conclusions. Ofloxacin possesses definite potential cause reactions in humans. These study data, concert surveillance suggest hierarchy among fluoroquinolones: fleroxacin ≫ lomefloxacin, pefloxacin ciprofloxacin > enoxacin, norfloxacin, ofloxacin. impact phototoxicity will have on selecting optimum member drug family appears be substantial outpatient ambulatory settings minimal inpatient settings.